Skip to main content
Signal8

CollPlant Biotechnologies Ltd (OPHI)

CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside developing solutions for medical aesthetics. All of CollPlant's offerings are underpinned by its proprietary plant-based genetic engineering technology, which facilitates the production of recombinant type I human collagen. Its diverse product portfolio encompasses BioInks engineered for 3D tissue and organ fabrication; dermal and soft tissue fillers designed to diminish wrinkles; and innovative breast implants, both 3D bioprinted and injectable, aimed at promoting breast tissue regeneration. CollPlant also provides a 3D bioprinted regenerative soft tissue matrix. Specialized products include VergenixSTR, a soft tissue repair matrix targeting tendinopathy, and VergenixFG, an advanced wound care treatment for deep surgical incisions and persistent wounds such as diabetic, venous, and pressure ulcers, burns, and bedsores. The company maintains strategic collaboration agreements with numerous partners, including 3D Systems Corporation, CellInk (a BICO Group company), the Advanced Regenerative Manufacturing Institute, the RegenMed Development Organization, Israel's Technion Institute of Technology, AbbVie, and STEMCELL. Established in Rehovot, Israel, in 2004, the company was formerly known as CollPlant Holdings Ltd. before adopting its current name in June 2019.

Sector: Orthopedic, Prosthetic & Surgical Appliances & Supplies

Industry: Medical - Specialties

CollPlant Biotechnologies Ltd. logo

CollPlant Biotechnologies Ltd.

NASDAQ:OPHIHealthcare
+17.17%$4.64
CLOSED
Mkt Cap$14.27M
EV-
Float1.25M
O/S3.08M
VOL27K sh
$ Vol$97K
RVOL0.36×
Inst Own-
SI2.9%
Net Cash/Sh-
Dilution
CollPlant Biotechnologies Ltd. logoNASDAQ:OPHIClosed$4.64+17.17%

CollPlant Biotechnologies Ltd (OPHI) dilution facts from SEC filings

Snapshot as of Dec 31, 2025, built from 55 SEC filings.

Shelf registration
F-3 filed Jul 9, 2026, effective Jul 16, 2026
Source: 424B3 filed Jul 17, 2026
At-the-market (ATM) program
No active program in the filings reviewed
Warrants outstanding
12 warrant series recorded as outstanding
Most recent offering
PIPE, closed Oct 14, 2026
Source: 6-K filed Oct 15, 2026

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro